申请人:STERLING DRUG INC.
公开号:EP0189853A2
公开(公告)日:1986-08-06
5-[1H-(5-membered-N-aromatic-heteryl)-1-yl]-7-R'-1,6-naphthyridin-2(1H)-ones (formula 1) or salts thereof are useful as cardiotonic agents. Also shown as intermediates are 5-X-7-R'-1,6-naphthyridin-2(1H)-ones (formula II) or salts thereof, where X is bromo, chloro or hydrazino, 2-[2-(di-lower-alkylamino)ethenyl)-1,6-dihydro-6-oxo-3-pyridinecarbonitrile (formula III), and 2-[2-(di-lower- alkylamino)-1-propenyl]-6-methoxy-3-pyridinecarbonitrile (formula IIIa). Processes shown include the preparation of I from II, preparation of II from III or IIIa and the preparation of III from 1,6-dihydro-2-methyl-6-oxo-3-pyridinecarbonitrile, and the preparation of IIIa from 6-methoxy-2-methyl-3-pyridinecarbonitrile.
5-[1H-(5-membered-N-aromatic-heteryl)-1-yl]-7-R'-1,6-萘啶-2(1H)-酮(式 1)或其盐可用作强心剂。作为中间体的还有 5-X-7-R'-1,6-萘啶-2(1H)-酮(式 II)或其盐(其中 X 为溴代、氯代或肼代)、2-[2-(二低级烷基氨基)乙烯基]-1,6-二氢-6-氧代-3-吡啶甲腈(式 III)和 2-[2-(二低级烷基氨基)-1-丙烯基]-6-甲氧基-3-吡啶甲腈(式 IIIa)。所示工艺包括由 II 制备 I,由 III 或 IIIa 制备 II,由 1,6-二氢-2-甲基-6-氧代-3-吡啶甲腈制备 III,以及由 6-甲氧基-2-甲基-3-吡啶甲腈制备 IIIa。